Cargando…
Chemotherapy of advanced breast cancer: outcome and prognostic factors.
The outcome for 758 consecutive patients who had received one or more chemotherapy regimens for recurrent or metastatic breast cancer is presented. The response rate following first line treatment was 34%. Median duration of response was 7.8 months, median time to progression was 3.7 months and medi...
Autores principales: | Gregory, W. M., Smith, P., Richards, M. A., Twelves, C. J., Knight, R. K., Rubens, R. D. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1993
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1968749/ https://www.ncbi.nlm.nih.gov/pubmed/8217615 |
Ejemplares similares
-
Do patients with advanced breast cancer benefit from chemotherapy?
por: Ramirez, A. J., et al.
Publicado: (1998) -
Advanced breast cancer: use of resources and cost implications.
por: Richards, M. A., et al.
Publicado: (1993) -
Chemotherapy of advanced breast cancer: a controlled randomized trial of cyclophosphamide versus a four-drug combination.
por: Rubens, R. D., et al.
Publicado: (1975) -
Iododoxorubicin in advanced breast cancer: a phase II evaluation of clinical activity, pharmacology and quality of life.
por: Twelves, C. J., et al.
Publicado: (1994) -
Weekly epirubicin for breast cancer with liver metastases and abnormal liver biochemistry.
por: Twelves, C. J., et al.
Publicado: (1989)